Allergan plc (NYSE:AGN) announced that it has received approval from the U.S. Food and Drug Administration or FDA to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21.
Biopharmaceutical company Apricus Biosciences, Inc (APRI) has signed an exclusive distribution agreement with Ferring Pharmaceuticals to market Vitaros, a topical on-demand product for the treatment of erectile dysfunction in Latin American countries.
"We rate APRICUS BIOSCIENCES INC (APRI) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most ...
Apricus Biosciences, Inc (NASDAQ:APRI) has been given a positive Growth Style Score by Zacks Research. The Growth score analyzes the growth prospects for a company in addition to analyzing company financials.